Start New EnglishEspañol中文РусскийالعربيةTiếng ViệtFrançaisDeutsch한국어Tagalog Library Performance
BETA v.3.0

2025 CPT code 81200

Analysis of the ASPA gene for common variants (e.g., E285A, Y231X).

Follow CPT guidelines for molecular pathology procedures.Report pre-lysis procedures separately.Use modifier 26 for interpretation and report only.Consider payer-specific guidelines.

Modifier 26 may be appended if only interpretation and reporting are performed by a physician.Other modifiers may apply based on specific circumstances (e.g., 59 for distinct procedural service, 90 for outside laboratory, 91 for repeat testing).

Medical necessity for this test is established by the presence of symptoms or family history suggestive of Canavan disease, or as part of newborn screening or carrier testing. Payer-specific guidelines may apply.Documentation supporting the clinical indication for testing is crucial.

The clinical responsibility lies with the laboratory analyst who performs the technical aspects of the test, including nucleic acid extraction, amplification, and detection. Physician interpretation, if separately ordered, is reported with a modifier (e.g., 26) and a separate code (e.g., G0452).

IMPORTANT:If pre-lysis procedures (e.g., microdissection, codes 88380 and 88381) are performed, they should be reported separately.For physician interpretation and report only, modifier 26 may be appended.Codes 87149-87153, 87471-87801, 87900-87904 (microbial identification), and 88271-88275, 88365-88368 (in situ hybridization) are used for other related tests.

In simple words: This lab test checks for common changes in the ASPA gene, which can cause Canavan disease. The test involves several steps to find these gene changes. The results show if the gene is changed or not.

This CPT code encompasses the analysis of the aspartoacylase (ASPA) gene to detect common variants, such as E285A and Y231X.The procedure includes all analytical steps: nucleic acid extraction (e.g., cell lysis, digestion), amplification, and detection of target gene variants.While the test typically includes all listed variants, it may also identify other unlisted variants.The results are qualitative unless otherwise specified.

Example 1: A patient presents with symptoms suggestive of Canavan disease.The physician orders the 81200 test to identify common ASPA gene variants to confirm or rule out the diagnosis., A newborn screening reveals a potential ASPA gene abnormality.The 81200 test is ordered for confirmatory testing and to determine the specific variant(s) present., A family history of Canavan disease prompts genetic testing.The 81200 test is ordered for at-risk family members to assess their carrier status or to identify disease-causing variants.

Detailed patient history, including symptoms, family history of Canavan disease (if applicable), and clinical indication for testing.Lab report indicating the specific ASPA gene variants identified (if any) and interpretation by a qualified healthcare professional if applicable.

** This code is for the analysis of common variants.Testing for additional uncommon variants should be included and not billed separately. Full gene sequencing should not be reported using this code unless explicitly stated in the code description.Always refer to the most up-to-date CPT codebook for accurate coding guidelines.

** Only Enterprise users with EHR integration can access case-specific answers. Click here to request access.

Discover what matters.

iFrame™ AI's knowledge is aligned with and limited to the materials uploaded by users and should not be interpreted as medical, legal, or any other form of advice by iFrame™.